$1.44+0.00 (+0.35%)
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Filana Therapeutics, Inc. in the Healthcare sector is trading at $1.44 with a market capitalization of $66M. Wall Street consensus targets $6.50 (2 analysts), implying a +353.0% move over the next 12 months. The stock is currently near its 52-week low of $1.16, remaining 38.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's dise...